-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, news about changes in pharmaceutical company executives has continued in the industry
.
Just entering November, four more pharmaceutical companies announced new executive appointments in just three days
.
WuXi Biologics On November 1, WuXi Biologics announced that Lu Shaohua has retired and resigned as chief financial officer to devote more time to his personal affairs
.
At the same time, Tu Ming took over as the chief financial officer and will be responsible for overseeing the group's financial strategy, performance, reporting and business planning, as well as operational support for funds, taxation, accounting management, and auditing
.
Yanming Biological On November 1, Yanming Biological announced that it has officially appointed Dr.
Jeffery Li, an expert in medicinal chemistry and tumor immune drug research and development, as the company's senior vice president of medicinal chemistry
.
Dr.
Li will work in Yanming Bio-Beijing R&D Center to establish and manage the medicinal chemistry, computational chemistry, chemical process and DMPK departments, responsible for the development of the company’s new targets from Hit Generation to clinical candidate compounds, and support the company’s multiple projects to reach the clinical stage
.
According to the data, before joining Yanming Biotechnology, Dr.
Li had served as an associate professor at Yanbian University, a visiting professor at Pohang University of Technology in South Korea, a researcher at Wayne State University in the United States, a chief scientist at Amgen, a senior director at Corvus Pharmaceuticals in the United States, and Senior Vice President of Pharmaceutical R&D and other positions
.
Junshi Biotech announced on November 1st that it had appointed Dr.
Virginia Ellen Maher as the vice president of medical sciences, responsible for the strategy formulation, guidance and supervision of the company’s clinical development projects throughout the cycle, and reported to the company’s Chief Medical Officer (CMO) Patricia Dr.
Keegan reports
.
It is understood that Dr.
Maher has 30 years of experience in the clinical research, drug administration and supervision of oncology drugs
.
Stellite On November 3, Stellite issued an announcement stating that at the seventeenth meeting of the fourth board of directors, the "Proposal on Election of the Company's Vice Chairman" was considered and passed.
.
The company's board of directors agreed to elect Shen Weiyi as the company's new vice chairman, whose term of office is from the date of review and approval of the board of directors to the date of expiry of the term of the board of directors
.
Analysts believe that the frequent wave of resignations in the pharmaceutical industry is the norm in the industry
.
According to incomplete statistics, since the second half of this year alone, dozens of senior executives from more than 40 pharmaceutical companies have resigned, including Hengrui Pharmaceuticals, Hisun Pharmaceuticals, North China Pharmaceuticals, Guangshengtang, Yanan Bikang, etc.
In addition to local pharmaceutical companies, foreign pharmaceutical companies such as Eli Lilly, AstraZeneca, Novo Nordisk, and Roche Pharmaceuticals are also involved
.
As some time ago, GlaxoSmithKline China successively announced the resignation of two senior executives, Wang Xinguang, vice president, head of Chinese corporate communications and government affairs, and Chen Ming, vice president, head of registration affairs, which attracted the attention of the industry
.
The industry predicts that, at present, the entire pharmaceutical sector, especially the scope of medical insurance, is facing greater pressure from medical insurance control fees, and the overall growth rate of the industry is gradually slowing down; and the epidemic situation has affected the R&D, clinical and sales stages of pharmaceutical companies.
Look, in the future, pharmaceutical companies will continue to adjust in order to respond to market changes, and this will also cause the flow of talents in the pharmaceutical market to continue to accelerate
.
.
Just entering November, four more pharmaceutical companies announced new executive appointments in just three days
.
WuXi Biologics On November 1, WuXi Biologics announced that Lu Shaohua has retired and resigned as chief financial officer to devote more time to his personal affairs
.
At the same time, Tu Ming took over as the chief financial officer and will be responsible for overseeing the group's financial strategy, performance, reporting and business planning, as well as operational support for funds, taxation, accounting management, and auditing
.
Yanming Biological On November 1, Yanming Biological announced that it has officially appointed Dr.
Jeffery Li, an expert in medicinal chemistry and tumor immune drug research and development, as the company's senior vice president of medicinal chemistry
.
Dr.
Li will work in Yanming Bio-Beijing R&D Center to establish and manage the medicinal chemistry, computational chemistry, chemical process and DMPK departments, responsible for the development of the company’s new targets from Hit Generation to clinical candidate compounds, and support the company’s multiple projects to reach the clinical stage
.
According to the data, before joining Yanming Biotechnology, Dr.
Li had served as an associate professor at Yanbian University, a visiting professor at Pohang University of Technology in South Korea, a researcher at Wayne State University in the United States, a chief scientist at Amgen, a senior director at Corvus Pharmaceuticals in the United States, and Senior Vice President of Pharmaceutical R&D and other positions
.
Junshi Biotech announced on November 1st that it had appointed Dr.
Virginia Ellen Maher as the vice president of medical sciences, responsible for the strategy formulation, guidance and supervision of the company’s clinical development projects throughout the cycle, and reported to the company’s Chief Medical Officer (CMO) Patricia Dr.
Keegan reports
.
It is understood that Dr.
Maher has 30 years of experience in the clinical research, drug administration and supervision of oncology drugs
.
Stellite On November 3, Stellite issued an announcement stating that at the seventeenth meeting of the fourth board of directors, the "Proposal on Election of the Company's Vice Chairman" was considered and passed.
.
The company's board of directors agreed to elect Shen Weiyi as the company's new vice chairman, whose term of office is from the date of review and approval of the board of directors to the date of expiry of the term of the board of directors
.
Analysts believe that the frequent wave of resignations in the pharmaceutical industry is the norm in the industry
.
According to incomplete statistics, since the second half of this year alone, dozens of senior executives from more than 40 pharmaceutical companies have resigned, including Hengrui Pharmaceuticals, Hisun Pharmaceuticals, North China Pharmaceuticals, Guangshengtang, Yanan Bikang, etc.
In addition to local pharmaceutical companies, foreign pharmaceutical companies such as Eli Lilly, AstraZeneca, Novo Nordisk, and Roche Pharmaceuticals are also involved
.
As some time ago, GlaxoSmithKline China successively announced the resignation of two senior executives, Wang Xinguang, vice president, head of Chinese corporate communications and government affairs, and Chen Ming, vice president, head of registration affairs, which attracted the attention of the industry
.
The industry predicts that, at present, the entire pharmaceutical sector, especially the scope of medical insurance, is facing greater pressure from medical insurance control fees, and the overall growth rate of the industry is gradually slowing down; and the epidemic situation has affected the R&D, clinical and sales stages of pharmaceutical companies.
Look, in the future, pharmaceutical companies will continue to adjust in order to respond to market changes, and this will also cause the flow of talents in the pharmaceutical market to continue to accelerate
.
